Public Notices: Peak Powder River Resources, LLC (F031172/A0016113)
Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
05/03/2024 | Press release | Distributed by Public on 05/03/2024 09:33
Please select the service you want to use:
Smartlinks | MustGrow Biologics Corp. | Finance | Security Markets | Security Markets | Company News | Chemicals | Manufacturing | Professional and Business Services | Legal Services | Securities Issuers | Agrochemicals Manufacturers | Frankfurt Stock Exchange | Berlin Stock Exchange | Stuttgart Stock Exchange | OTC Markets | Canadian Securities Exchange (CSE) | Cboe Canada | Omega ATS | Lynx ATS | Nasdaq CX2 | Nasdaq CXC
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact